Survival Analysis of Patients with Interval Cancer Undergoing Gastric Cancer Screening by Endoscopy

Chisato Hamashima1*, Michiko Shabana2, Mikizo Okamoto3, Yoneatsu Osaki3, Takuji Kishimoto3

1 Cancer Screening Assessment and Management Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan, 2 Department of Internal Medicine, San-in Rosai Hospital, Yonago, Tottori Prefecture, Japan, 3 Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori Prefecture, Japan

* chamashi@ncc.go.jp

Abstract

Aims
Interval cancer is a key factor that influences the effectiveness of a cancer screening program. To evaluate the impact of interval cancer on the effectiveness of endoscopic screening, the survival rates of patients with interval cancer were analyzed.

Methods
We performed gastric cancer-specific and all-causes survival analyses of patients with screen-detected cancer and patients with interval cancer in the endoscopic screening group and radiographic screening group using the Kaplan-Meier method. Since the screening interval was 1 year, interval cancer was defined as gastric cancer detected within 1 year after a negative result. A Cox proportional hazards model was used to investigate the risk factors associated with gastric cancer-specific and all-causes death.

Results
A total of 1,493 gastric cancer patients (endoscopic screening group: n = 347; radiographic screening group: n = 166; outpatient group: n = 980) were identified from the Tottori Cancer Registry from 2001 to 2008. The gastric cancer-specific survival rates were higher in the endoscopic screening group than in the radiographic screening group and the outpatients group. In the endoscopic screening group, the gastric cancer-specific survival rate of the patients with screen-detected cancer and the patients with interval cancer were nearly equal (P = 0.869). In the radiographic screening group, the gastric cancer-specific survival rate of the patients with screen-detected cancer was higher than that of the patients with interval cancer (P = 0.009). For gastric cancer-specific death, the hazard ratio of interval cancer in the endoscopic screening group was 0.216 for gastric cancer death (95%CI: 0.054-0.868) compared with the outpatient group.
Conclusion

The survival rate and the risk of gastric cancer death among the patients with screen-detected cancer and patients with interval cancer were not significantly different in the annual endoscopic screening. These results suggest the potential of endoscopic screening in reducing mortality from gastric cancer.

Introduction

Gastric cancer is the third leading cause of cancer death in both sexes worldwide, with its number reaching about 723,000 in 2012 [1]. Although half of the total number of gastric cancer has been reported in Eastern Asia, the burden of gastric cancer has also remained in Eastern and South Europe. In most countries, gastric cancer screening has not been commonly carried out, except in Korea and Japan which have performed gastric cancer screening as a national program [2, 3]. The Japanese screening program for gastric cancer is limited to upper gastrointestinal series using barium meal (i.e., radiographic screening), whereas the Korean screening program consists of both radiographic and endoscopic screenings. However, studies evaluating mortality reduction from gastric cancer by endoscopic screening remain limited [4, 5].

Mortality reduction from gastric cancer is a long-term effect of gastric cancer screening. On the other hand, evaluation of interval cancer can provide an early estimate of the impact of screening programs [6]. Interval cancer is defined as cases that are diagnosed after negative results of screening in the periods between routine and scheduled screenings [6]. The rate of interval cancer and the survival rate are directly affected the effectiveness of the cancer screening program. The sensitivity of endoscopic screening was previously calculated based on the rate of interval cancer using cancer registry data [7, 8]. On the other hand, there are only a few studies related to survival analysis of patients with gastric cancer detected by endoscopic screening [9, 10]. The survival of patients with interval cancer in endoscopic screening also remains unclear. To evaluate the impact of interval cancer on the effectiveness of endoscopic screening, the survival rates of patients with interval cancer were analyzed and compared with those of patients with screen-detected cancers between endoscopic and radiographic screenings based on the Tottori Cancer Registry in Japan.

Methods

Screening programs

The subjects of our study were selected from gastric cancer cases registered in 4 cities (i.e., Tottori, Yonago, Kurayoshi, and Sakaiminato) in Tottori Prefecture, Japan. Endoscopic screening has been conducted in Tottori, Yonago, and Sakaiminato since 2000 and in Kurayoshi since 2001. Gastric cancer screening is offered annually by local governments, and both radiography and endoscopy are used in these cities. All individuals aged 40 years and over can participate in the gastric cancer screening programs. There is no upper age limit for the target population for gastric cancer screening. Individuals can choose either endoscopy or radiography for gastric cancer screening based on their preference. Since the introduction of endoscopic screening, the participation rate in gastric cancer screening has increased, although the participation rate in gastric cancer screening involving both methods has remained at about 25% [11].

Physicians who can perform endoscopic screening were approved by the local committee for gastric cancer screening based on certain requirements [11]. Although endoscopic
screening has been performed in clinical settings, the results have been evaluated based on monitor screen review by the local committee, including experienced endoscopists in each city.

Target group

The subjects of our study were selected from gastric cancer cases registered in 4 cities (Tottori, Yonago, Kurayoshi, and Sakaiminato) in the Tottori Cancer Registry from 2001 to 2008. There were 2,066 potential subjects with gastric cancer in the 4 cities in Tottori Prefecture. Detailed information of all the potential cases was obtained from the local cancer registries, and the following cases were excluded: patients who 1) were more than 80 years old and less than 39 years old at the time of gastric cancer diagnosis, 2) had registry duplication, 3) lacked the diagnosis date for gastric cancer, or 4) had a diagnosis other than gastric cancer. The selected patients with gastric cancers were divided into 3 groups according to the detection process used in the participant list of gastric cancer screening from 2000 to 2006 in the 4 cities. Screening histories were investigated from the participant lists and matching was based on name, sex, and birthday. When there was no screening history, the patients were defined as belonging to the outpatient group.

The screening group was divided into patients with screen-detected cancer and patients with interval cancer based on the screening results. Patients with screen-detected cancer patients were identified after a positive result of gastric cancer screening. Since the screening interval of both endoscopic screening and radiographic screening was 1 year, interval cancer was defined as cancer detected within 1 year after a negative result on cancer screening.

Follow-up

Follow-up was continued from the date of diagnosis to the date of death or up to December 31, 2011 based on the Tottori Cancer Registry. The mean follow-up period was 66.4 ± 38.6 months. Since the local cancer registry system did not collect the stages of all gastric cancers, we obtained detailed information from the database for gastric cancer screening of the Tottori Medical Association. However, information on gastric cancer patients who had never been screened was not available. Tumor location was recorded using the Japanese Classification of Gastric Carcinoma [12], in which the stomach is anatomically divided into 3 portions: upper, middle, and lower. Clinical stage was determined based on the Japanese Classification of Gastric Carcinoma [12]. Gastric cancers were also classified histologically into intestinal and diffuse types according to Lauren’s criteria [13].

Statistical analysis

The characteristics of the target groups were compared using the chi-square test. Survival analysis was performed using the Kaplan-Meier method with the log-rank test. The obtained curves show the proportion of individuals alive over time starting at the time of cancer diagnosis. Gastric cancer-specific survival and all-causes survival rates were calculated. A Cox proportional hazards model was used to investigate the risk factors associated with gastric cancer death and all-causes death for the endoscopic and radiographic screening group. Analyses were carried out using STATA 13.0 (STATA, College Station, TX, USA). All test statistics were two tailed, and P values of < 0.05 were considered to indicate a statistically significant difference.

Ethics statement

This study used the data of the local cancer registry and the population lists of gastric cancer screening. These were not included in the informed consents for the collection of the screening
results and health data. Based on the Japanese guideline for epidemiological studies developed by the national government, informed consent is not required for an observational study using secondary data without human materials [14]. Our study was survival analysis using the secondary data from the local cancer registry and the population lists of gastric cancer screening. Therefore, obtaining informed consent was waived in this study based on the Japanese guideline for epidemiological studies. This was confirmed by the Institutional Review Board of the National Cancer Center of Japan. Finally, this study was approved by the Institutional Review Board of the National Cancer Center of Japan on October 22, 2007.

**Results**

The procedure used for the selection of the target population is shown in Fig 1. A total of 2,066 subjects were selected from the Tottori Cancer Registry, of which 237 patients were not within the target age for the analysis. Most subjects who were excluded from the target group were more than 80 years old at the time of diagnosis, which was not the actual target for cancer screening. Two patients who had registry duplication, 44 patients who were not cases of gastric cancers, and 270 patients in whom the date of diagnosis was unclear were also excluded. From the list of participants with gastric cancer screening from 2000 to 2006, 20 patients whose screening methods were unclear were excluded. The remaining 1,493 patients were finally divided into 3 groups according to the cancer detection procedure as follows: endoscopic screening group (n = 347), radiographic screening group (n = 166), and outpatient group (n = 980; symptoms detected in outpatients). In the endoscopic screening group, the number of patients with screen-detected cancer was 324 and that of patients with interval cancer was 23. In the radiographic screening group, the number of patients with screen-detected cancer was 143 and that of patients with interval cancer was 23.

The results of the comparison of the basic characteristics of the endoscopic screening group, radiographic screening group, and outpatient group are shown in Table 1. The proportion of male patients was significantly higher than that of female patients in all groups. The age distribution was different between the 3 groups. Although more than 50% of the patients in the endoscopic and radiographic screening groups were 70 years and over, the proportion of the 70 years and over age group was lower in the outpatient group than in both the endoscopic and radiographic screening groups.

In the outpatient group, detailed information could not be obtained from the Tottori Cancer Registry, and the clinical stage and location were unknown in more than 70% of the patients in the outpatient group. The characteristics of the patients with screen-detected cancer and patients with interval cancer were compared between the endoscopic and radiographic screening groups (Table 2). The proportion of stage I was approximately 50% among the screen-detected cancer in the endoscopic screening and radiographic screening groups. The clinical stage was unknown in most of the patients with interval cancer. The clinical stage distribution was not significantly different between the endoscopic screening group and the radiographic screening group (P = 0.415). The numbers of screen-detected cancer according to histological types using both screening methods were also not significantly different (P = 0.581).

The results of the Kaplan-Meier analysis of survival in patients with gastric cancer detected by screening and outpatients are shown in Fig 2A. The 5-year survival rates were 91.2 ± 1.5% (95%CI: 87.5–93.8) for the endoscopic screening group, 84.3 ± 2.9% (95%CI: 78.5–90.8) for the radiographic screening group, and 66.0 ± 1.6% (95%CI: 62.8–68.9) for the outpatient group. There were significant differences in the gastric cancer-specific survival rate between the endoscopic screening group and the outpatient group (P < 0.001), as well as between the radiographic screening group and the outpatient group (P < 0.001). The gastric cancer-specific rate
was significantly higher in the patients in the endoscopic screening group than in the patients in the radiographic screening group (P = 0.013). There were significant differences in the all-causes survival rates between the endoscopic screening group and the outpatient group (P < 0.001) (Fig 2B). The all-causes survival rates of the radiographic screening group were also significantly higher than those of the outpatient group (P = 0.011). There were significant differences in the all-causes survival rates between the endoscopic screening group and the radiographic group (P = 0.001).
The gastric cancer-specific survival rates of the patients with screen-detected cancer and patients with interval cancer in the screening groups are shown in Fig 3A. In the endoscopic screening group, the 5-year survival rate of the patients with screen-detected cancer was 91.9 ± 1.6% (95%CI: 87.5–93.8) and that of the patients with interval cancer was 91.3 ± 5.9% (95%CI: 69.5–97.8). In the radiographic screening group, the 5-year survival rate of the patients with screen-detected cancer was 86.8 ± 2.9% (95%CI: 79.9–91.5) and that of the patients with interval cancer was 68.7 ± 2.9% (95%CI: 45.2–83.7). In the endoscopic screening group, there were no significant differences in the gastric cancer-specific survival rates between the patients with screen-detected cancer and the patients with interval cancer (P = 0.869). The gastric cancer-specific survival rate was significantly higher in the patients with interval cancer in the endoscopic screening group than in the outpatient group (P = 0.018). In the radiographic screening group, there was a significant difference in the gastric cancer-specific survival rates between the patients with screen-detected cancer and the patients with interval cancer (P = 0.009). The gastric cancer-specific survival rate of the patients with interval cancer in the radiographic screening was not significantly different from that of the patients in the outpatient group (P = 0.961).

The all-causes survival rates of the patients with screen-detected cancer and patients with interval cancer patients in the screening groups are shown in Fig 3B. In the endoscopic screening group, there were no significant differences in the all-causes cancer survival rates between the patients with screen-detected cancer and the patients with interval cancer (P = 0.786). The all-causes survival rate of the patients with interval cancer in the endoscopic screening group was significantly higher than that of the patients in the outpatient group (P = 0.047). In the radiographic screening group, the all-causes survival rates of the patients with screen-detected cancer were significantly higher than those of the patients with interval cancer (P = 0.045). The all-causes survival rate of the patients with interval cancer in the radiographic screening was not significantly different from that of the patients in the outpatient group (P = 0.771).

The results of the Cox proportional hazards analysis of gastric cancer death and all-causes death in the endoscopic screening group, radiographic screening group, and outpatient group are shown in Table 3. Compared with the risk of the outpatient group for gastric cancer death, the hazard ratio of interval cancer in the endoscopic screening group was lower (0.216, 95%CI: 0.054–0.868), but that of interval cancer in the radiographic screening group was equal (1.020, 95%CI: 0.506–2.055). There were no differences among sex, age group, and city in which the patients lived. For all-causes death, although the hazard ratio of the interval cancer in the endoscopic screening group was lower, it was not significantly different (0.420, 95%CI: 0.174–1.014).

Table 1. Basic characteristics of the endoscopic screening group, radiographic screening group, and outpatient group.

|                          | Endoscopic screening group | Radiographic screening group | Outpatient group | P-value |
|--------------------------|---------------------------|-------------------------------|------------------|---------|
|                          | Number of patients (%)    | Number of patients (%)        | Number of patients (%) |       |
| Total number             | 347                       | 166                          | 980              |         |
| Age group                |                           |                               |                  |         |
| 40–49 years              | 9                         | 2.6                           | 0.6              | 94      | 9.6    | < 0.001|
|                         |                           |                               |                  |         |
| 50–59 years              | 25                        | 7.2                           | 15               | 9.0     | 254    | 25.9   |
|                         |                           |                               |                  |         |
| 60–69 years              | 122                       | 35.2                          | 46               | 27.7    | 273    | 27.9   |
|                         |                           |                               |                  |         |
| 70–79 years              | 191                       | 55.0                          | 104              | 62.7    | 359    | 36.6   |
| Sex                      |                           |                               |                  |         |
| Male                     | 226                       | 65.1                          | 98               | 59.0    | 710    | 72.4   | < 0.001|
| Female                   | 121                       | 34.9                          | 68               | 41.0    | 270    | 27.6   |

doi:10.1371/journal.pone.0126796.t001
The risk factors associated with gastric cancer-specific death and all-causes death in the endoscopic screening group and radiographic screening group were also analyzed (Table 4). For gastric cancer death, the hazard ratio of interval cancer in the endoscopic screening group was nearly equal to that of screen-detected cancer in the endoscopic screening group (0.886, 95% CI 0.530–1.454).
CI: 0.213–3.691). Although the hazard ratio of screen-detected cancer in the radiographic screening group was 1.506, it was not significantly different (95% CI: 0.871–2.603). The hazard ratios of interval cancer in the radiographic screening group were always significantly higher: 4.352 for gastric cancer death (95% CI: 2.009–9.427) and 3.091 for all-causes death (95% CI: 1.634–5.849). In the endoscopic screening group, since the hazard ratio of interval cancer was 0.886 for gastric cancer death (95% CI: 0.213–3.691) and 1.117 for all-causes death (95% CI: 0.450–2.771), the risk of interval cancer was nearly equal to that of screen-detected cancer.

Discussion

The present study showing the survival rate of patients with interval cancer indicated that the endoscopic screening group had a better prognosis than the radiographic screening group and outpatient group, as demonstrated by the results of gastric cancer-specific survival and all-causes survival analyses. The survival rate and the risk of gastric cancer death for patients with interval cancer were similar to those of patients with screen-detected cancer in the endoscopic screening group. Thus, interval cancer can potentially be used as an indicator for predicting the early effects of cancer screening. Interval cancer includes cases missed at the previous screening and cases which appeared because they grew rapidly as the preclinical phase (sojourn time) was shorter than the screening interval [15, 16]. Because of the good prognosis of interval cancer in endoscopic screening, the results suggest a possibility of reducing mortality from gastric cancer by endoscopic screening. However, this can be misleading because the survival rate of patients with screen-detected cancers is overestimated by length bias, lead time bias and over-diagnosis. Since we used the survival rate of patients with screen-detected cancers for comparison, there is a need for prudent interpretation of the survival rate of patients with interval cancer in the present study.

On the other hand, sensitivity can also be a factor for predicting the effectiveness of cancer screening. Greater sensitivity leads to high cancer detection rates during screening and lower interval cancer rates. Several studies have reported that the sensitivity of endoscopic screening is usually higher than that of radiographic screening [7, 8]. This implies that the rate of interval cancer is lower in endoscopic screening than in radiographic screening. Since endoscopic screening has a potential to detect early-stage cancer, localized cancer was reportedly more frequent in patients who had undergone endoscopic screening than in those who had undergone radiographic screening [8, 17, 18]. In mammographic screening, several studies have shown that interval cancers and screen-detected cancers have different clinicopathologic characteristics [15, 16, 19–21]. Although we could not obtain detailed information regarding the specific clinical stage of the interval cancers, the interval cancers on endoscopic screening for gastric cancer in a previous study were early-stage cancers only, whereas those on radiographic screening included late-stage cancers [7].

The survival rates of patients with interval cancer have been reported to be lower than those of patients with screen-detected cancer in mammographic screening [19, 20]. In the present study involving endoscopic screening for gastric cancer, the survival rates of the patients with
screen-detected cancer and the patients with interval cancers were not significantly different and higher than that of patients in the outpatient group. The risk of gastric cancer death from interval cancer in the endoscopic screening group was similar to that of gastric cancer death from screen-detected cancer in the endoscopic screening group. Although the screening interval was 1 year for endoscopic screening and radiographic screening in the study areas, a better prognosis might be expected for endoscopic screening. These results suggest that it may be possible to extend the endoscopic screening interval to more than 1 year. In fact, mortality reduction was shown in the screening programs in Korea with a screening interval of 2 years [8]. Although the number of endoscopic examinations has rapidly increased in Japan [22], insufficient capacity may be more of a barrier for endoscopic screening not to be introduced in local

Table 3. Cox proportional hazard analysis of gastric cancer death and all-causes death in the endoscopic screening group, radiographic screening group, and outpatient group.

| Characteristics                        | Gastric cancer death (HR | 95%CI) | P-value | All-causes death (HR | 95%CI) | P-value |
|----------------------------------------|--------------------------|--------|---------|----------------------|--------|---------|
| Group                                  |                          |        |         |                      |        |         |
| Outpatient group                       | 1                        | -      | -       | 1                    | -      | -       |
| Screen-detected cancer by endoscopic screening | 0.245 (0.171–0.350)    | < 0.001 | 0.385 (0.297–0.497) | < 0.001 |        |
| Interval cancer in endoscopic screening | 0.216 (0.054–0.868)     | 0.031  | 0.420 (0.174–1.014) | 0.054   |        |
| Screen-detected cancer by radiographic screening | 0.368 (0.236–0.571)    | < 0.001 | 0.647 (0.481–0.870) | 0.004   |        |
| Interval cancer in radiographic screening | 1.020 (0.506–2.055)   | 0.957  | 1.104 (0.607–2.008) | 0.746   |        |
| Sex                                    |                          |        |         |                      |        |         |
| Male                                   | 1                        | -      | -       | 1                    | -      | -       |
| Female                                 | 0.961 (0.776–1.191)     | 0.718  | 0.772 (0.640–0.932) | 0.007   |        |
| Age                                    |                          |        |         |                      |        |         |
| 40–49 years                            | 1                        | -      | -       | 1                    | -      | -       |
| 50–59 years                            | 1.109 (0.699–1.759)     | 0.660  | 1.121 (0.732–1.717) | 0.600   |        |
| 60–69 years                            | 1.230 (0.793–1.907)     | 0.355  | 1.385 (0.926–2.070) | 0.113   |        |
| 70–79 years                            | 1.346 (0.879–2.060)     | 0.172  | 1.902 (1.291–2.804) | 0.001   |        |
| City                                   |                          |        |         |                      |        |         |
| Tottori                                 | 1                        | -      | -       | 1                    | -      | -       |
| Yonago                                 | 0.881 (0.702–1.105)     | 0.273  | 0.975 (0.810–1.175) | 0.794   |        |
| Kurayoshi                              | 1.154 (0.841–1.585)     | 0.374  | 1.133 (0.856–1.501) | 0.383   |        |
| Sakaiminato                            | 0.732 (0.484–1.110)     | 0.142  | 0.743 (0.523–1.056) | 0.098   |        |

doi:10.1371/journal.pone.0126796.t003
Table 4. Cox proportional hazard analysis of gastric cancer death and all-causes death for the endoscopic screening group and radiographic screening group.

| Characteristics                        | Gastric cancer death | All-causes death |
|----------------------------------------|----------------------|------------------|
|                                        | HR (95%CI)           | P-value          | HR (95%CI) | P-value |
| **Group**                              |                      |                  |            |         |
| Screen-detected cancer by endoscopic screening | 1                    | -                | -          | 1        | -    |
| Interval cancer in endoscopic screening | 0.886 (0.213–3.691) | 0.868            | 1.117 (0.450–2.771) | 0.811 |
| Screen-detected cancer by radiographic screening | 1.506 (0.871–2.603) | 0.143            | 1.642 (1.136–2.373) | 0.008 |
| Interval cancer in radiographic screening | 4.352 (2.009–9.427) | < 0.001          | 3.091 (1.634–5.849) | 0.001 |
| **Sex**                                |                      |                  |            |         |
| Male                                   | 1                    | -                | -          | 1        | -    |
| Female                                 | 0.786 (0.467–1.325)  | 0.367            | 0.465 (0.311–0.695) | < 0.001 |
| **Age**                                |                      |                  |            |         |
| 40–49 years                            | 1                    | -                | -          | 1        | -    |
| 50–59 years                            | 1.718 (0.211–13.969) | 0.613            | 2.001 (0.250–16.014) | 0.513 |
| 60–69 years                            | 0.964 (0.128–7.247)  | 0.972            | 1.771 (0.242–12.979) | 0.574 |
| 70–79 years                            | 1.333 (0.183–9.707)  | 0.776            | 3.249 (0.453–23.321) | 0.241 |
| **City**                               |                      |                  |            |         |
| Tottori                                | 1                    | -                | -          | 1        | -    |
| Yonago                                 | 1.208 (0.722–2.022)  | 0.472            | 1.188 (0.832–1.695) | 0.343 |
| Kurayoshi                              | 0.423 (0.058–3.105)  | 0.397            | 0.512 (0.125–2.098) | 0.352 |
| Sakaiminato                            | 0.757 (0.294–1.951)  | 0.564            | 0.663 (0.330–1.333) | 0.249 |
| **Location**                           |                      |                  |            |         |
| U                                      | 1                    | -                | -          | 1        | -    |
| M                                      | 0.237 (0.130–0.430)  | < 0.001          | 0.390 (0.259–0.588) | < 0.001 |
| L                                      | 0.338 (0.184–0.620)  | < 0.001          | 0.413 (0.264–0.656) | < 0.001 |
| Unknown                                | 0.532 (0.127–2.238)  | 0.389            | 0.944 (0.402–2.219) | 0.895 |
| **Stage**                              |                      |                  |            |         |
| I                                      | 1                    | -                | -          | 1        | -    |
| II                                     | 7.343 (2.831–19.045) | < 0.001          | 2.458 (1.330–4.543) | 0.004 |
| III                                    | 13.154 (5.539–31.237)| < 0.001          | 3.197 (1.789–5.712) | < 0.001 |
| IV                                     | 52.876 (20.820–134.284)| < 0.001       | 12.244 (5.967–25.124) | < 0.001 |
| Unknown                                | 4.881 (2.287–10.418) | < 0.001          | 1.760 (1.179–2.626) | 0.006 |
| **Histology**                          |                      |                  |            |         |
| Intestinal type                        | 1                    | -                | -          | 1        | -    |
| Diffuse type                           | 3.403 (2.028–5.711)  | < 0.001          | 1.639 (1.134–2.367) | 0.009 |
| Others                                 | 2.663 (0.361–19.639) | 0.337            | 2.964 (0.934–9.404) | 0.065 |
| Unknown                                | 3.956 (1.518–10.310) | 0.005            | 2.179 (1.051–4.515) | 0.036 |

Group
HR, hazard ratio; CI, confidence interval

doi:10.1371/journal.pone.0126796.t004
communities. If the screening interval can be extended, endoscopic screening may be used efficiently even with limited resources.

A notable constraint of the present study is the lack of data regarding the clinical stage of the interval cancer. To evaluate the effects of interval cancer, follow-up of the participants of a population-based screening based on the cancer registry is needed. In Japan, cancer registries have not yet been prepared at the national level, and the registry method has not yet been standardized as of 2014 [23, 24]. The Tottori Cancer Registry is one of the most reliable systems with a long history in Japan. Although information about disease extension has been obtained as an alternative item for the clinical stage, this information is often lacking [25]. The quality of the Tottori Cancer Registry was, however, not optimal since the percentage of death-certification-only cases was 15.1% in 2007 which was lower than the national average [26]. Even if there was a notification of new cases in the cancer registration system, detailed information was often lacking because the clinical stage was not a necessary item. Fortunately, additional information could be obtained for the screening group from the Tottori Medical Association database because the association has the responsibility of implementing gastric cancer screening programs and collecting detailed information for quality assurance. However, we could not obtain additional detailed information regarding the numbers of medical institutions in Tottori Prefecture for the outpatient group and the interval cancer cases in both screening groups. These limitations prevented us from obtaining stage information sufficiently, thus careful interpretation of the results in reference to these contains is required.

This study has other limitations. First, the background difference should be considered between the endoscopic screening group and the radiographic screening group. Endoscopic screening has been performed in clinical practice in Tottori Prefecture. The age of the participants in endoscopic screening was more advanced than that of the participants in radiographic screening [7]. Individuals aged more than 70 years could be screened by physicians using endoscopy in their own private practice. Since younger people who have family physicians were fewer than older people who have family physicians, there was little opportunity for the younger people to be tested in clinical practice. Second, since there was no information as to whether or not the patients participated in opportunistic screenings, the outpatient group might include cancer patients which were detected by these screenings. Selection bias may also be considered in the selection of the screening method at the individual level. Third, the survival rate was different among hospitals in Japan [27]. Moreover, the present results are limited to local areas in Japan. Finally, subgroup analysis could not be adequately performed because of the small sample size.

In conclusion, the gastric cancer-specific and all-causes survival rates of patients with screen-detected cancers and patients with interval cancers were nearly equal in the annual endoscopic screening. The risk of gastric cancer death was lower in the patients with screen-detected and interval cancers in the endoscopic screening group than in the outpatient group. These results suggest the potential of endoscopic screening in reducing mortality from gastric cancer. However, additional studies must be performed to more extensively evaluate mortality reduction from gastric cancer by endoscopic screening as well as to investigate the impact of interval cancer on the effectiveness of endoscopic screening for gastric cancer.

Acknowledgments

The authors would like to thank the Tottori Cancer Registry office and the local government of Tottori, Yonago, Kurayoshi, and Sakaiminto for their cooperation with the study.

The authors also thank Ms. Kanoko Matsushima, Ms. Junko Asai and Ms. Mayumi Kobayashi for secretarial work.
We are also grateful to Dr. Edward F. Barroga, Associate Professor and Senior Medical Editor of Tokyo Medical University for the editing of the English manuscript.

**Author Contributions**

Conceived and designed the experiments: CH TK. Performed the experiments: MS MO YO. Analyzed the data: CH TK. Contributed reagents/materials/analysis tools: CH MS. Wrote the paper: CH TK.

**References**

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. Available: [http://globocan.iarc.fr/](http://globocan.iarc.fr/).

2. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008; 38: 259–267. doi: [10.1093/jjco/hyn017](http://dx.doi.org/10.1093/jjco/hyn017) PMID: 18344316

3. Kim Y, Jun JK, Choi KS, Lee HY, Park EC. Overview of the national cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev. 2011; 12: 725–730. PMID: 21627372

4. Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013; 8: e79088. doi: [10.1371/journal.pone.0079088](http://dx.doi.org/10.1371/journal.pone.0079088) PMID: 24236091

5. Cho BY. Evaluation of the validity of current national health screening programs and plans to improve the system. 2014. (In Korean)

6. European Commission. Follow up of the target population and ascertainment of interval cancers. In: Perry N, Broeders M, Wolf CD, Tornberg S, Holland R, Karsa LV, editors. European guidelines for quality assurance in breast cancer screening and diagnosis 4th Edition. Luxembourg: European Commission; 2006. pp. 35–42.

7. Hamashima C, Okamoto M, Shabana M, Osaki Y, Kishimoto T. Sensitivity of endoscopic screening for gastric cancer by the incidence method. Int J Cancer. 2013; 133: 653–659. doi: [10.1002/ijc.28065](http://dx.doi.org/10.1002/ijc.28065) PMID: 23364866

8. Choi KS, Jun JK, Park EC, Park S, Jung KW, Han MA, et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012; 7: e50041. doi: [10.1371/journal.pone.0050041](http://dx.doi.org/10.1371/journal.pone.0050041) PMID: 23209638

9. Matsumoto S, Ishikawa S, Yoshida Y. Reduction of gastric cancer mortality by endoscopic and radiographic screening in an isolated island: A retrospective cohort study. Aust J Rural Health. 2013; 21: 319–332. doi: [10.1111/ajr.12064](http://dx.doi.org/10.1111/ajr.12064) PMID: 24299436

10. Nishida M, Okamoto M, Hamashima C, Osaki Y, Kishimoto T. Evaluation of endoscopic screening for gastric cancer by survival rate. J Younago Med Ass. 2009; 60: 184–191. (in Japanese)

11. Shabana M, Hamashima C, Nishida M, Miura K, Kishimoto T. Current status and evaluation of endoscopic screening for gastric cancer. Jpn J Cancer Detection & Diagnosis. 2010; 17: 229–235. (in Japanese)

12. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. Tokyo: Kanehara & Co., Ltd.; 2010

13. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64: 31–49. PMID: 14320675

14. Ministry of Health, Welfare and Labour. Japanese ethical guidelines for epidemiological studies; 2007.

15. Kalager M, Tamimi RM, Bretthauer M, Adami HO. Prognosis in women with interval breast cancer: population based observational cohort study. BMJ. 2012; 345: e7536. doi: [10.1136/bmj.e7536](http://dx.doi.org/10.1136/bmj.e7536) PMID: 23160783

16. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999; 91: 2020–2028. PMID: 10580027

17. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006; 12: 4873–4874. PMID: 16937471

18. Choi KS, Jun JK, Suh M, Park B, Noh DK, Song SH, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015; 112: 608–612. doi: [10.1038/bjc.2014.608](http://dx.doi.org/10.1038/bjc.2014.608) PMID: 25490528
19. Bordás P, Jonsson H, Nyström L, Lenner P. Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast. 2007; 16: 47–54. PMID: 16875820

20. Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with interval breast cancer—results from the breast cancer screening programme in Malmö, Sweden 1976–1999. J Med Screen. 2007; 14: 138–143. PMID: 17925086

21. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer. 1995; 31A: 1830–1835. PMID: 8541108

22. Ministry of Health, Labour and Welfare. Medical Institute Survey, 2011. 2012. Available: http://www.e-stat.go.jp/SG1/estat/GL08020101.do?_toGL08020101_&tstatCode=000001030908&requestSender = dsearch

23. Sobue T. Current activities and future directions of the cancer registration system in Japan. Int J Clin Oncol. 2008; 13: 97–101. doi: 10.1007/s10147-008-0761-7 PMID: 18463951

24. Matsuda T, Sobue T. Recent trends in population-based cancer registries in Japan: the Act on Promotion of Cancer Registries and drastic changes in the historical registry. Int J Clin Oncol. 2015; 20: 11–20. doi:10.1007/s10147-014-0765-4 PMID: 25351534

25. Okamoto N. A history of the cancer registration system in Japan. Int J Clin Oncol. 2008; 13: 90–96. doi: 10.1007/s10147-008-0759-1 PMID: 18463950

26. Sobue T, Matsuda T, Shibata A, Matsuda A. Monitoring of Cancer Incidence in Japan 2007. Tokyo: National Cancer Center, Center for Cancer Control and Information Services; 2012 pp. 140.

27. Research Group for Survival statistics of Japanese association of Clinical Cancer Centers. Survival analysis of cancer patients by the Kaplan-Meier method. 2012. Available: http://www.gunma-cc.jp/sarukihan/seizonritu/index.html.